EUVIMEDEUVIMED entdecken
Crossref

Intravitreal Dexamethasone Implant in the Treatment of Diabetic Macular Edema Focusing on the Role of OCT Biomarkers

Tomáš Mudroch, Michal Hrevuš, Marta Karhanová, Jiří Řehák, Klára Marešová

Czech and Slovak Ophthalmology · 20.06.2024 · (AoP)

DOI: 10.31348/2024/29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, online erschienen am 20.06.2024. Verfasst von Tomáš Mudroch und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Dexamethasone, Intravitreal Injections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to evaluate the outcomes of Ozurdex® (DEX) implant in patients with diabetic macular edema (DME) in real-world clinical practice, and to determine the correlation between known OCT biomarkers and the effect of treatment. Material and Methods: This retrospective study included 42 eyes of 33 patients (16 women, 17 men) treated with DEX at the Department of Ophthalmology, Faculty of Medicine and Dentistry of Palacký University and University Hospital Olomouc for DME indication between 2020 and 2023. Follow-up examinations were conducted at 1, 3, and 6 months after the first DEX application. The main assessed parameters were: best-corrected visual acuity (BCVA), intraocular pressure (IOP), central retinal thickness (CRT), OCT biomarkers. The results were subsequently statistically evaluated.

Results

At the first follow-up after DEX application, there was an average decrease in CRT of 186 ±146µm and a gain of 3 ±7 letters. Positive morphological and functional responses were observed in 39 eyes (92.9%) and 23 eyes (54.8%) respectively. The disorganization of retinal inner layers (DRIL) biomarker was initially present in 41 eyes (97.6%), with reduction or disappearance observed in 13 eyes (31%) post-application. Eyes with ellipsoid zone disruption (EZ disruption) had an average initial BCVA of 49.6 letters, compared to 57.8 letters in the group without this biomarker. The mean gain in BCVA was +8.7 letters in treatment-naive eyes and +2.1 letters in previously treated eyes. Chronic DME was less frequent in treatment-naive (n = 1, 14.3%) compared to previously treated eyes (n = 28, 84.8%). All these results were statistically significant (p < 0.05). An increase in IOP post-DEX application occurred in 9 patients (21.4%).

Conclusion

Our results confirm DEX as a safe and effective treatment option for DME. Treatment-naive patients achieved better functional outcomes. We confirmed ellipsoid zone disruption (EZ disruption) as a negative biomarker. Additionally, we demonstrated the capacity of DEX to reduce disorganization of the retinal inner layers (DRIL).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyDexamethasoneIntravitreal InjectionsDrug ImplantsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedVisual AcuityGlucocorticoidsTomography, Optical Coherence

Stichwörter der Autor:innen

OCT biomarkersOzurdexdexamethasonediabetic macular edema

Substanzen

DexamethasoneDrug ImplantsGlucocorticoids

Zitieren

APA

Mudroch, T., Hrevuš, M., Karhanová, M., Řehák, J., & Marešová, K. (2024). Intravitreal Dexamethasone Implant in the Treatment of Diabetic Macular Edema Focusing on the Role of OCT Biomarkers. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2024/29

Vancouver

Mudroch T, Hrevuš M, Karhanová M, Řehák J, Marešová K. Intravitreal Dexamethasone Implant in the Treatment of Diabetic Macular Edema Focusing on the Role of OCT Biomarkers. Czech and Slovak Ophthalmology. 2024. doi:10.31348/2024/29

BibTeX
@article{Mudroch2024,
  author = {Mudroch, Tomáš and Hrevuš, Michal and Karhanová, Marta and Řehák, Jiří and Marešová, Klára},
  title = {Intravitreal Dexamethasone Implant in the Treatment of Diabetic Macular Edema Focusing on the Role of OCT Biomarkers},
  journal = {Czech and Slovak Ophthalmology},
  year = {2024},
  number = {AoP},
  doi = {10.31348/2024/29}
}
Kostenlos starten →